CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
Nae-Yun Heo, Young-Suk Lim, Han Chu Lee, Yung Sang Lee, Kang Mo Kim, Kwan Soo Byun, Kwang-Hyub Han, Kwan Sik Lee, Seung Woon Paik, Seung Kew Yoon, Dong Jin Suh
Clin Mol Hepatol. 2013;19(1):60-69.   Published online 2013 March 25    DOI: https://doi.org/10.3350/cmh.2013.19.1.60

Excel Download

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
Clinical and Molecular Hepatology. 2013;19(1):60   Crossref logo
Link1 Link2 Link3

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial
Hepatology. 2003;38:244-245   Crossref logo
Link1 Link2

Treatment of chronic hepatitis C: Efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients
The Korean Journal of Hepatology. 2008;14(4):443   Crossref logo
Link1 Link2 Link3

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C
Alimentary Pharmacology & Therapeutics. 2003;17(5):687-694   Crossref logo
Link1 Link2 Link3

W1017 Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin
Gastroenterology. 2008;134(4):A-833   Crossref logo
Link1 Link2

PIN19 THE COST-EFFECTIVENESS ANALYSIS OF COMBINATION OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS COMBINATION OF PEGINTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND
Value in Health. 2004;7(3):356   Crossref logo
Link1 Link2

Peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2A (roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC)
Journal of Hepatology. 2003;38:139-140   Crossref logo
Link1 Link2

Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin
Alimentary Pharmacology & Therapeutics. 2007;27(5):433-440   Crossref logo
Link1 Link2

792 CLINICAL AND PERSISTENCY OUTCOMES IN HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B PLUS RIBAVIRIN
Journal of Hepatology. 2008;48:S295-S296   Crossref logo
Link1 Link2

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
Hepatology. 2002;35(4):930-936   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.